Determining values of prognostic factors with patients with NSCLC based on two years survival Source: Annual Congress 2007 - Lung neoplasms Year: 2007
Prognostic factors affecting survival in advanced non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004
Effects of prognostic factors on survival of the patients of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 326s Year: 2005
Clinical factors of long-term survival in patients with advanced lung cancer Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
Assessing the relevance of biological prognostic indices in predicting survival in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Influence of the limited lung function to the outcome of the surgical treatment in patients with NSCLC Source: Annual Congress 2003 - Lung function testing for preoperative evaluation in lung cancer patients Year: 2003
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011
Validity of predictive estimate by physicians of the survival of patients with recently diagnosed stages IIIB and IV non-small cells lung cancer (NSCLC) Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
The predictive value of neuroendocrine markers for response to chemotherapy and survival in patients with non-small cell lung Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Antigen a in blood correlates with improved survival in resected NSCLC patients Source: Eur Respir J 2007; 30: Suppl. 51, 669s Year: 2007
Effects of pretreatment prognostic factors and treatment on survival in advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019
Timing of radiotherapy and possible survival benefit in limited disease SCLC patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Quantification of telomerase activity is important in predicting prognosis of patients with non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 482s Year: 2005
Effect of cardiovascular comorbidities on the survival patients with stage I and II non-small-cell lung cancer Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Epidemiological and clinical predictors of survival during the first year of the treatment in non-small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
Rates of treatment response and median survival in advanced non small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011
Clinical and biological predictors of progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated by erlotinib in the ERMETIC cohort Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010